Cytosorbents Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation (Nasdaq: CTSO) on April 5, 2022, reporting events occurring on April 1, 2022. The filing addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes.
Material Changes
- Board Expansion: The Board of Directors increased its size from five to six members.
- New Appointment: Ms. Jiny Kim was appointed to fill the resulting vacancy.
- Background: Ms. Kim is currently a Vice President at Zimmer Biomet, managing the Smart Implants portfolio. She previously held leadership roles at LivaNova and Johnson & Johnson Medical Devices.
- Compensation: Ms. Kim will receive standard non-employee director compensation. Committee assignments have not yet been determined.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The only unusual item noted is the specific appointment of a new director with a background in orthopedic smart implants.
Investor Verification Checklist
- Verify the press release (Exhibit 99.1) for additional details on Ms. Kim's strategic fit.
- Monitor future filings for Ms. Kim's specific committee assignments.
- Review the company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K does not contain financial statements.